H-RAS-MA119726

Adenoviral-Mediated Anti-H-ras Ribozyme for the Treatment of Bladder Cancer

Bladder cancer is the fifth most common malignancy, demonstrated by the approx 52,900 patients that will be diagnosed in the United States in 1996 (1 ). Around 15–20% of these patients will be characterized by muscle invasion or node posmve

Tissue-Specific Delivery of an anti-H-ras Ribozyme Against Malignant Melanoma

Malignant melanoma is an increasingly important clinical problem in the United States, because the incidence of cutaneous malignant melanoma has been increasing significantly in recent years (1 ,2 ) Despite the use of cancer chemotherapy

PNAS：RAS 抑制剂又添一员，新型蛋白模拟物或为癌症治疗

-5 结合到了 Ras 的 Sos 结合位点。图片来源：PNASRas 突变调控细胞对 Sos 蛋白模拟物的摄取和作用Sos 蛋白模拟物对细胞发挥调节作用需要进入细胞内部。活细胞荧光显微镜和流式细胞术显示，Ras 突变的膀胱和肺癌细胞中，细胞显著摄取荧光素标记的 CHDSos-5 进入胞浆。Ras 突变的癌细胞对 CHDSos-5 的摄取增强表明 Sos 蛋白类似物可能对这些细胞有选择性的毒性。基于这一前提，研究团队探索了 CHDSos-5 与 H-Ras 突变型结合的可能性。野生型和 G